An Open-label Study to Evaluate the Utility of the Apoptosis Imaging Biomarker 18F]ML10 to Assess the Response to Chemotherapy in Patients With Non-Hodgkin's Lymphoma(NHL).
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- changes in [18F]ML10 uptake in tumours
研究概览
简要总结
This study aims to evaluate the potential of 2-(5- Fluoro pentyl)-2-methyl malonic acid ([18F]ML10), as an apoptosis imaging biomarker and its potential to predict response in patients with Non Hodgkin's Lymphoma.
详细描述
Apoptosis or programmed cell death mechanisms are disrupted in cancer cells allowing them to live longer and grow faster than normal cells. Apoptosis is a key target for several novel anti-cancer agents. A biomarker that could permit imaging levels of ongoing apoptosis could be a powerful tool in associated drug development programs by providing relevant data to support proof of concept. In addition, use in the clinical setting may permit the tailoring of treatment for individual patients balancing efficacy of treatment with known toxicity levels. This study aims to evaluate the potential of 2-(5- Fluoro pentyl)-2-methyl malonic acid ([18F]ML10), as an apoptosis imaging biomarker and its potential to predict response in patients with Non Hodgkin's Lymphoma. All patients will have a baseline [18F]ML10 PET-CT scan and a post-treatment scan after the initiation of the first course of intravenous chemotherapy. The study aims to enrol unto 16 subjects with Non-Hodgkins Lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of giving written informed consent, and willing and able to comply with the requirements and restrictions listed in the consent form.
- •Male or female patients >18 years of age at screening with histological or cytological diagnosis of Non-Hodgkin's Lymphoma and due to receive intravenous chemotherapy for the first time
- •A female subject is eligible to participate if she has non-childbearing potential
- •Male subject must agree to use one of the contraception methods listed
- •Able to lie comfortably on back for up to 70 minutes at a time.
- •WHO performance status 0, 1 or 2 -
排除标准
- •Patients with known history of Hepatitis B, C, non-A, non-B and HIV
- •Any clinically significant medical conditions that in the opinion of the investigator would compromise the compliance with study procedures.
- •Pregnant or breast feeding females.
- •Any other prior anticancer therapy
- •Any new investigational agent, including an investigational anti-cancer agent
- •History of sensitivity to heparin or heparin-induced thrombocytopenia.
- •Males and females not able to comply with contraceptive guidelines during the study.
结局指标
主要结局
changes in [18F]ML10 uptake in tumours
时间窗: between baseline at day 0 and between 14-20 days after
Extent of changes in \[18F\]ML10 uptake in tumours following chemotherapy using visual and semi-quantitative parameters.
次要结局
- alterations in [18F]ML10 uptake with tumour volume and tumour metabolic changes(between baseline at day 0 and between 14-20 days after)
- voxel-based uptake map of [18F]ML10 in the target lesion(between baseline at day 0 and between 14-20 days after)